출판 : MarketsandMarkets (마켓츠앤마켓츠) 출판년월 : 2023년06월
양전자 방출 단층 촬영 시장 : 제품(독립형 PET 시스템, PET/CT 시스템, PET/MRI 시스템), 용도(종양학, 심장병학, 신경학), 최종 사용자(병원 및 수술 센터, 진단, 이미지 클리닉), 지역별 – 2028년까지 세계 예측
Positron Emission Tomography Market by Product (Standalone PET Systems, PET/CT Systems, PET/MRI Systems), Application (Oncology, Cardiology, Neurology), End User (Hospitals & Surgical Centers, Diagnostic & Imaging Clinics) & Region – Global Forecasts to 2028
| 페이지수 | 169 |
| 도표수 | 147 |
| 구성 | 영문조사보고서 |
| 가격 |
The global positron emission tomography market is projected to reach USD 3.5 billion by 2028 from USD 2.5 billion in 2023, at a CAGR of 6.6% from 2023 to 2028. Factors such as the high incidence/prevalence of target diseases, growing number of diagnostic imaging centers/procedures, increasing awareness about the benefits of early diagnosis of diseases, and the rapid adoption of technologically advanced imaging systems are responsible for the increasing growth of this market.
세계 양전자 방출 단층 촬영 시장은 2023년 25억 달러에서 2028년 35억 달러에 달할 것으로 예상되며, 2023년부터 2028년까지 연평균 6.6% 성장할 것으로 예상됩니다. 대상 질병의 높은 발병률/유병률, 진단 영상 센터/시술의 증가, 질병 조기 진단의 이점에 대한 인식 증가, 기술적으로 진보된 영상 시스템의 빠른 채택등이 시장성장 증가에 요인이라 할 수 있습니다.
“The low-slice sub-segment of PET/CT segment held the largest share of the market in 2022”
Based on product, the positron emission tomography market is segmented into standalone PET systems, PET/CT systems, and PET/MRI systems. The PET/CT segment of the market is further divided into low-slice, medium-slice, and high-slice scanners. The low-slice PET/CT systems subsegment held major share in the market. The systems are particularly useful for imaging small areas, such as the brain, thyroid, or extremities. Moreover, the advantages offered, including lower cost, smaller size, and faster scan times led to the major share of the segment.
“The cardiovascular applications segment is projected to register the highest CAGR during the forecast period”
Based on application, the positron emission tomography market is broadly categorized into oncology, neurological, cardiovascular, and other applications. Advancements in PET scanner technology is expected to drive the adoption of these systems for cardiovascular application. Modern PET scanners offer improved image resolution, faster imaging times, and the ability to combine PET with other imaging modalities such as computed tomography (CT). This integration allows for more comprehensive assessments, enabling the simultaneous evaluation of cardiac structure, function, and perfusion, leading to accurate cardiac disease diagnosis.
“The market in the Asia Pacific region is expected to witness the highest growth during the forecast period.”
The positron emission tomography market in the APAC region is expected to register a CAGR during the forecast period, primarily due to the rapid economic growth in emerging APAC countries, increasing healthcare investments, improvements in healthcare systems, and the flourishing medical tourism market in APAC countries,.
A breakdown of the primary participants referred to for this report is provided below:
• By Company Type: Tier 1–48%, Tier 2–36%, and Tier 3– 16%
• By Designation: Director-level–14%, C-level–10%, and Others–76%
• By Region: North America–40%, Europe–32%, Asia Pacific–22%, and RoW–6%
The prominent players in the positron emission tomography market are GE Healthcare (US), Koninklijke Philips N.V. (Netherlands), Siemens Healthineers (Germany), Shanghai United Imaging Healthcare (China), Canon Inc. (Japan), Shimadzu Corporation (Japan), Mediso Ltd. (Hungary), Minfound Medical System Ltd. (China), and Neusoft Corporation (China), among others.
Research Coverage
This report studies the positron emission tomography market based on product, application, enduser, and region. It also covers the factors affecting market growth, analyzes the various opportunities and challenges in the market, and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their growth trends and forecasts the revenue of the market segments with respect to five main regions (and the respective countries in these regions).
Reasons to Buy the Report
The report will help the market leaders/new entrants with information on the closest approximations of the revenue numbers for the overall positron emission tomography market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key market drivers, restraints, challenges, and opportunities.
This report provides insights on the following pointers:
• Analysis of key drivers (rising target patient population, growing adoption of multimodal PET imaging devices, technological advancement, and increasing investment, funds, and grants by public-private organizations), restraints (high capital and operational cost, unfavorable regulatory guidelines), opportunities (improving healthcare infrastructure across emerging countries, PET utilization for breast imaging, promising product pipeline), and challenges (availability of alternate imaging technologies) influencing the growth of the positron emission tomography market
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the positron emission tomography market
• Market Development: Comprehensive information about lucrative markets–the report analyses the positron emission tomography market across varied regions
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the positron emission tomography market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players like GE Healthcare (US), Koninklijke Philips N.V. (Netherlands), Siemens Healthineers (Germany), Canon Inc. (Japan), Shimadzu Corporation (Japan), and Minfound Medical System Ltd. (China).
목차
1 INTRODUCTION 23
1.1 STUDY OBJECTIVES 23
1.2 MARKET DEFINITION 23
1.2.1 INCLUSIONS AND EXCLUSIONS 24
1.3 MARKETS COVERED 24
1.3.1 MARKET SEGMENTATION 24
1.3.2 GEOGRAPHIC SEGMENTATION 25
1.4 YEARS CONSIDERED 25
1.5 CURRENCY CONSIDERED 25
1.6 LIMITATIONS 26
1.7 STAKEHOLDERS 26
2 RESEARCH METHODOLOGY 27
2.1 RESEARCH DATA 27
FIGURE 1 RESEARCH DESIGN 28
2.1.1 SECONDARY RESEARCH 28
2.1.2 PRIMARY RESEARCH 30
2.1.2.1 Primary sources 30
2.1.2.2 Key industry insights 31
2.1.2.3 Breakdown of primaries 31
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 31
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 32
2.2 RECESSION IMPACT 32
2.3 MARKET SIZE ESTIMATION 33
FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 34
2.3.1 BOTTOM-UP APPROACH 34
2.3.1.1 Approach 1: Company revenue estimation approach 34
FIGURE 5 MARKET SIZE ESTIMATION FOR PET SYSTEMS: APPROACH 1 (COMPANY REVENUE ESTIMATION) 35
FIGURE 6 REVENUE SHARE ANALYSIS: ILLUSTRATIVE EXAMPLE OF GE HEALTHCARE 35
2.3.1.2 Approach 2: Customer-based market estimation 36
FIGURE 7 POSITRON EMISSION TOMOGRAPHY MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH 36
2.3.1.3 CAGR projection 37
FIGURE 8 CAGR PROJECTION: SUPPLY-SIDE ANALYSIS 37
2.4 DATA VALIDATION APPROACH 38
FIGURE 9 DATA TRIANGULATION METHODOLOGY 38
2.5 MARKET SHARE ASSESSMENT 39
2.6 STUDY ASSUMPTIONS 39
2.7 RISK ASSESSMENT 40
2.7.1 POSITRON EMISSION TOMOGRAPHY MARKET: RISK ASSESSMENT 40
2.8 GROWTH RATE ASSUMPTIONS 40
3 EXECUTIVE SUMMARY 41
FIGURE 10 POSITRON EMISSION TOMOGRAPHY MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION) 41
FIGURE 11 POSITRON EMISSION TOMOGRAPHY MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION) 42
FIGURE 12 POSITRON EMISSION TOMOGRAPHY MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 42
FIGURE 13 GEOGRAPHICAL SNAPSHOT: POSITRON EMISSION TOMOGRAPHY MARKET 43
4 PREMIUM INSIGHTS 44
4.1 POSITRON EMISSION TOMOGRAPHY MARKET OVERVIEW 44
FIGURE 14 RISING PREVALENCE OF TARGET DISEASES TO DRIVE GROWTH 44
4.2 NORTH AMERICA: POSITRON EMISSION TOMOGRAPHY MARKET, BY PRODUCT (USD MILLION) 45
FIGURE 15 PET/CT SYSTEMS SEGMENT TO DOMINATE NORTH AMERICAN MARKET DURING FORECAST PERIOD 45
4.3 ASIA PACIFIC: POSITRON EMISSION TOMOGRAPHY MARKET, BY END USER (USD MILLION) 45
FIGURE 16 HOSPITALS AND SURGICAL CENTERS FORM LARGEST END-USER SEGMENT IN ASIA PACIFIC MARKET 45
4.4 GLOBAL PET/CT SYSTEMS MARKET, BY TYPE 46
FIGURE 17 LOW-SLICE SCANNERS SEGMENT TO HOLD LARGEST SHARE DURING FORECAST PERIOD 46
4.5 GEOGRAPHIC SNAPSHOT OF POSITRON EMISSION TOMOGRAPHY MARKET 46
FIGURE 18 CHINA TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD 46
5 MARKET OVERVIEW 47
5.1 INTRODUCTION 47
5.2 MARKET DYNAMICS 47
FIGURE 19 POSITRON EMISSION TOMOGRAPHY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 47
5.2.1 DRIVERS 48
5.2.1.1 Rising target patient population 48
FIGURE 20 NUMBER OF PET PROCEDURES, BY COUNTRY, 2019 VS. 2022 48
5.2.1.2 Growing adoption of multimodal PET imaging devices 48
5.2.1.3 Technological advancements in radiopharmaceuticals and PET systems 49
5.2.1.4 Increasing investments, funds, and grants by public-private organizations 49
5.2.2 RESTRAINTS 50
5.2.2.1 High capital and operational costs 50
5.2.2.2 Unfavorable regulatory guidelines 50
5.2.3 OPPORTUNITIES 51
5.2.3.1 Improving healthcare infrastructure across emerging economies 51
5.2.3.2 Increasing use of PET in breast cancer detection 51
5.2.3.3 Promising product pipeline 51
5.2.4 CHALLENGES 52
5.2.4.1 Availability of alternate imaging technologies 52
5.3 PORTER’S FIVE FORCES ANALYSIS 52
TABLE 1 POSITRON EMISSION TOMOGRAPHY MARKET: PORTER’S FIVE FORCES ANALYSIS 52
5.3.1 THREAT OF NEW ENTRANTS 52
5.3.2 THREAT OF SUBSTITUTES 53
5.3.3 BARGAINING POWER OF SUPPLIERS 53
5.3.4 BARGAINING POWER OF BUYERS 53
5.3.5 INTENSITY OF COMPETITIVE RIVALRY 53
5.4 VALUE CHAIN ANALYSIS 53
5.4.1 RESEARCH & DEVELOPMENT 53
5.4.2 PROCUREMENT AND PRODUCT DEVELOPMENT 54
5.4.3 MARKETING, SALES AND DISTRIBUTION, AND POST-SALES SERVICES 54
FIGURE 21 VALUE CHAIN ANALYSIS—MAXIMUM VALUE ADDED DURING MANUFACTURING PHASE 54
5.5 SUPPLY CHAIN ANALYSIS 54
5.5.1 PROMINENT COMPANIES 54
5.5.2 SMALL & MEDIUM-SIZED ENTERPRISES 55
5.5.3 END USERS 55
TABLE 2 SUPPLY CHAIN ECOSYSTEM 55
FIGURE 22 SUPPLY CHAIN ANALYSIS 56
5.6 ECOSYSTEM COVERAGE 56
5.7 PATENT ANALYSIS 57
FIGURE 23 PATENT DETAILS FOR POSITRON EMISSION TOMOGRAPHY (JANUARY 2013–APRIL 2023) 57
FIGURE 24 PATENT DETAILS FOR PET/CT SYSTEMS (JANUARY 2013–APRIL 2023) 58
FIGURE 25 PATENT DETAILS FOR PET/MRI SYSTEMS (JANUARY 2013–APRIL 2023) 59
5.8 TRADE ANALYSIS 60
5.8.1 TRADE ANALYSIS: POSITRON EMISSION TOMOGRAPHY MARKET 60
TABLE 3 IMPORT DATA FOR POSITRON EMISSION TOMOGRAPHY (HS CODE 902212), BY COUNTRY, 2018–2022 (USD) 60
TABLE 4 EXPORT DATA FOR POSITRON EMISSION TOMOGRAPHY (HS CODE 902212), BY COUNTRY, 2018–2022 (USD) 60
5.9 KEY CONFERENCES AND EVENTS (2023–2025) 61
TABLE 5 POSITRON EMISSION TOMOGRAPHY MARKET: LIST OF MAJOR CONFERENCES AND EVENTS 61
5.10 TECHNOLOGY ANALYSIS 62
5.11 CASE STUDIES 63
5.11.1 TECHNOLOGICAL CHALLENGES 63
TABLE 6 CASE STUDY 1: DEVELOPING AND IMPROVING MEDICAL IMAGING TECHNOLOGIES 63
5.11.2 LOWERING DEPENDENCE ON CONTRACT MANUFACTURING 63
TABLE 7 CASE STUDY 2: DEPENDENCE ON CONTRACT MANUFACTURING AND OUTSOURCING 63
5.12 PRICING ANALYSIS 64
TABLE 8 REGION-WISE PRICE RANGE FOR PET SYSTEMS 64
5.13 REGULATORY ANALYSIS 64
5.13.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 64
TABLE 9 LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 64
5.13.1.1 North America 64
5.13.1.2 Europe 65
5.13.1.3 Asia 65
6 POSITRON EMISSION TOMOGRAPHY MARKET, BY PRODUCT 66
6.1 INTRODUCTION 67
TABLE 10 POSITRON EMISSION TOMOGRAPHY MARKET, BY PRODUCT, 2020–2028 (USD MILLION) 67
TABLE 11 POSITRON EMISSION TOMOGRAPHY MARKET, BY PRODUCT, 2020–2028 (UNITS) 67
6.2 STANDALONE PET SYSTEMS 67
6.2.1 FEWER TECHNOLOGICAL ADVANCEMENTS TO AFFECT MARKET GROWTH 67
TABLE 12 STANDALONE PET SYSTEMS MARKET, BY REGION, 2020–2028 (USD MILLION) 68
TABLE 13 STANDALONE PET SYSTEMS MARKET, BY APPLICATION, 2020–2028 (USD MILLION) 68
TABLE 14 STANDALONE PET SYSTEMS MARKET, BY END USER, 2020–2028 (USD MILLION) 69
6.3 PET/CT SYSTEMS 69
TABLE 15 PET/CT SYSTEMS MARKET, BY TYPE, 2020–2028 (USD MILLION) 70
TABLE 16 PET/CT SYSTEMS MARKET, BY REGION, 2020–2028 (USD MILLION) 70
TABLE 17 PET/CT SYSTEMS MARKET, BY APPLICATION, 2020–2028 (USD MILLION) 70
TABLE 18 PET/CT SYSTEMS MARKET, BY END USER, 2020–2028 (USD MILLION) 71
6.3.1 LOW-SLICE SCANNERS 71
6.3.1.1 Smaller size and lower cost of scanners to drive growth 71
TABLE 19 PET/CT SYSTEMS MARKET FOR LOW-SLICE SCANNERS, BY REGION, 2020–2028 (USD MILLION) 72
TABLE 20 PET/CT SYSTEMS MARKET FOR LOW-SLICE SCANNERS, BY APPLICATION, 2020–2028 (USD MILLION) 72
TABLE 21 PET/CT SYSTEMS MARKET FOR LOW-SLICE SCANNERS, BY END USER, 2020–2028 (USD MILLION) 73
6.3.2 MEDIUM-SLICE SCANNERS 73
6.3.2.1 Better picture resolution to propel growth 73
TABLE 22 PET/CT SYSTEMS MARKET FOR MEDIUM-SLICE SCANNERS, BY REGION, 2020–2028 (USD MILLION) 74
TABLE 23 PET/CT SYSTEMS MARKET FOR MEDIUM-SLICE SCANNERS, BY APPLICATION, 2020–2028 (USD MILLION) 74
TABLE 24 PET/CT SYSTEMS MARKET FOR MEDIUM-SLICE SCANNERS, BY END USER, 2020–2028 (USD MILLION) 75
6.3.3 HIGH-SLICE SCANNERS 75
6.3.3.1 Increased patient throughput to boost growth 75
TABLE 25 PET/CT SYSTEMS MARKET FOR HIGH-SLICE SCANNERS, BY REGION, 2020–2028 (USD MILLION) 76
TABLE 26 PET/CT SYSTEMS MARKET FOR HIGH-SLICE SCANNERS, BY APPLICATION, 2020–2028 (USD MILLION) 76
TABLE 27 PET/CT SYSTEMS MARKET FOR HIGH-SLICE SCANNERS, BY END USER, 2020–2028 (USD MILLION) 77
6.4 PET/MRI SYSTEMS 77
6.4.1 INCREASING NUMBER OF INSTALLED SYSTEMS TO PROPEL GROWTH 77
TABLE 28 PET/MRI SYSTEMS MARKET, BY REGION, 2020–2028 (USD MILLION) 78
TABLE 29 PET/MRI SYSTEMS MARKET, BY APPLICATION, 2020–2028 (USD MILLION) 78
TABLE 30 PET/MRI SYSTEMS MARKET, BY END USER, 2020–2028 (USD MILLION) 79
7 POSITRON EMISSION TOMOGRAPHY MARKET, BY APPLICATION 80
7.1 INTRODUCTION 81
TABLE 31 POSITRON EMISSION TOMOGRAPHY MARKET, BY APPLICATION, 2020–2028 (USD MILLION) 81
7.2 ONCOLOGY APPLICATIONS 81
7.2.1 LAUNCH OF ADVANCED PET SCANNERS FOR DIAGNOSING AND TREATING CANCER TO DRIVE GROWTH 81
TABLE 32 POSITRON EMISSION TOMOGRAPHY MARKET FOR ONCOLOGY APPLICATIONS, BY REGION, 2020–2028 (USD MILLION) 82
7.3 NEUROLOGICAL APPLICATIONS 82
7.3.1 INCREASING PREVALENCE OF NEUROLOGICAL DISORDERS TO DRIVE GROWTH 82
TABLE 33 POSITRON EMISSION TOMOGRAPHY MARKET FOR NEUROLOGICAL APPLICATIONS, BY REGION, 2020–2028 (USD MILLION) 83
7.4 CARDIOVASCULAR APPLICATIONS 83
7.4.1 INCREASING GERIATRIC POPULATION TO DRIVE GROWTH 83
TABLE 34 POSITRON EMISSION TOMOGRAPHY MARKET FOR CARDIOVASCULAR APPLICATIONS, BY REGION, 2020–2028 (USD MILLION) 84
7.5 OTHER APPLICATIONS 84
TABLE 35 POSITRON EMISSION TOMOGRAPHY MARKET FOR OTHER APPLICATIONS, BY REGION, 2020–2028 (USD MILLION) 85
8 POSITRON EMISSION TOMOGRAPHY MARKET, BY END USER 86
8.1 INTRODUCTION 87
TABLE 36 POSITRON EMISSION TOMOGRAPHY MARKET, BY END USER, 2020–2028 (USD MILLION) 87
8.2 HOSPITALS AND SURGICAL CENTERS 87
8.2.1 MODALITY INTEGRATION ADVANTAGES TO DRIVE GROWTH 87
TABLE 37 POSITRON EMISSION TOMOGRAPHY MARKET FOR HOSPITALS AND SURGICAL CENTERS, BY REGION, 2020–2028 (USD MILLION) 88
8.3 DIAGNOSTIC AND IMAGING CLINICS 88
8.3.1 GROWING GERIATRIC POPULATION AND CLINICAL VOLUMES TO SUPPORT MARKET GROWTH 88
TABLE 38 POSITRON EMISSION TOMOGRAPHY MARKET FOR DIAGNOSTIC AND IMAGING CLINICS, BY REGION, 2020–2028 (USD MILLION) 89
8.4 AMBULATORY CARE CENTERS 89
8.4.1 ENHANCED COLLABORATION BETWEEN HOSPITALS AND AMBULATORY CENTERS TO DRIVE GROWTH 89
TABLE 39 POSITRON EMISSION TOMOGRAPHY MARKET FOR AMBULATORY CARE CENTERS, BY REGION, 2020–2028 (USD MILLION) 90
8.5 OTHER END USERS 90
TABLE 40 POSITRON EMISSION TOMOGRAPHY MARKET FOR OTHER END USERS, BY REGION, 2020–2028 (USD MILLION) 90
9 POSITRON EMISSION TOMOGRAPHY MARKET, BY REGION 91
9.1 INTRODUCTION 92
TABLE 41 POSITRON EMISSION TOMOGRAPHY MARKET, BY REGION, 2020–2028 (USD MILLION) 92
9.2 NORTH AMERICA 92
FIGURE 26 NORTH AMERICA: POSITRON EMISSION TOMOGRAPHY MARKET SNAPSHOT 93
TABLE 42 NORTH AMERICA: POSITRON EMISSION TOMOGRAPHY MARKET, BY COUNTRY, 2020–2028 (USD MILLION) 93
TABLE 43 NORTH AMERICA: POSITRON EMISSION TOMOGRAPHY MARKET, BY PRODUCT, 2020–2028 (USD MILLION) 94
TABLE 44 NORTH AMERICA: PET/CT SYSTEMS MARKET, BY TYPE, 2020–2028 (USD MILLION) 94
TABLE 45 NORTH AMERICA: POSITRON EMISSION TOMOGRAPHY MARKET, BY APPLICATION, 2020–2028 (USD MILLION) 94
TABLE 46 NORTH AMERICA: POSITRON EMISSION TOMOGRAPHY MARKET, BY END USER, 2020–2028 (USD MILLION) 95
9.2.1 US 95
9.2.1.1 Rising geriatric population to boost growth 95
TABLE 47 US: KEY TARGET DISEASE STATISTICS 96
TABLE 48 US: POSITRON EMISSION TOMOGRAPHY MARKET, BY PRODUCT, 2020–2028 (USD MILLION) 96
TABLE 49 US: PET/CT SYSTEMS MARKET, BY TYPE, 2020–2028 (USD MILLION) 97
9.2.2 CANADA 97
9.2.2.1 Focus on reducing healthcare costs and government investments to drive growth 97
TABLE 50 CANADA: POSITRON EMISSION TOMOGRAPHY MARKET, BY PRODUCT, 2020–2028 (USD MILLION) 97
TABLE 51 CANADA: PET/CT SYSTEMS MARKET, BY TYPE, 2020–2028 (USD MILLION) 98
9.3 EUROPE 98
TABLE 52 EUROPE: POSITRON EMISSION TOMOGRAPHY MARKET, BY COUNTRY, 2020–2028 (USD MILLION) 98
TABLE 53 EUROPE: POSITRON EMISSION TOMOGRAPHY MARKET, BY PRODUCT, 2020–2028 (USD MILLION) 99
TABLE 54 EUROPE: PET/CT SYSTEMS MARKET, BY TYPE, 2020–2028 (USD MILLION) 99
TABLE 55 EUROPE: POSITRON EMISSION TOMOGRAPHY MARKET, BY APPLICATION, 2020–2028 (USD MILLION) 99
TABLE 56 EUROPE: POSITRON EMISSION TOMOGRAPHY MARKET, BY END USER, 2020–2028 (USD MILLION) 100
9.3.1 GERMANY 100
9.3.1.1 Increasing prevalence of chronic diseases to boost growth 100
TABLE 57 GERMANY: POSITRON EMISSION TOMOGRAPHY MARKET, BY PRODUCT, 2020–2028 (USD MILLION) 101
TABLE 58 GERMANY: PET/CT SYSTEMS MARKET, BY TYPE, 2020–2028 (USD MILLION) 101
9.3.2 FRANCE 101
9.3.2.1 Increasing target patient population to propel growth 101
TABLE 59 FRANCE: POSITRON EMISSION TOMOGRAPHY MARKET, BY PRODUCT, 2020–2028 (USD MILLION) 102
TABLE 60 FRANCE: PET/CT SYSTEMS MARKET, BY TYPE, 2020–2028 (USD MILLION) 102
9.3.3 UK 103
9.3.3.1 Government initiatives to support market growth 103
TABLE 61 UK: POSITRON EMISSION TOMOGRAPHY MARKET, BY PRODUCT, 2020–2028 (USD MILLION) 103
TABLE 62 UK: PET/CT SYSTEMS MARKET, BY TYPE, 2020–2028 (USD MILLION) 103
9.3.4 ITALY 104
9.3.4.1 Availability of reimbursement coverage to fuel growth 104
TABLE 63 ITALY: POSITRON EMISSION TOMOGRAPHY MARKET, BY PRODUCT, 2020–2028 (USD MILLION) 104
TABLE 64 ITALY: PET/CT SYSTEMS MARKET, BY TYPE, 2020–2028 (USD MILLION) 104
9.3.5 SPAIN 105
9.3.5.1 Increasing prevalence of cancer to drive growth 105
TABLE 65 SPAIN: POSITRON EMISSION TOMOGRAPHY MARKET, BY PRODUCT, 2020–2028 (USD MILLION) 105
TABLE 66 SPAIN: PET/CT SYSTEMS MARKET, BY TYPE, 2020–2028 (USD MILLION) 106
9.3.6 REST OF EUROPE 106
TABLE 67 REST OF EUROPE: POSITRON EMISSION TOMOGRAPHY MARKET, BY PRODUCT, 2020–2028 (USD MILLION) 106
TABLE 68 REST OF EUROPE: PET/CT SYSTEMS MARKET, BY TYPE, 2020–2028 (USD MILLION) 107
9.4 ASIA PACIFIC 107
FIGURE 27 ASIA PACIFIC: POSITRON EMISSION TOMOGRAPHY MARKET SNAPSHOT 108
TABLE 69 ASIA PACIFIC: POSITRON EMISSION TOMOGRAPHY MARKET, BY COUNTRY, 2020–2028 (USD MILLION) 109
TABLE 70 ASIA PACIFIC: POSITRON EMISSION TOMOGRAPHY MARKET, BY PRODUCT, 2020–2028 (USD MILLION) 109
TABLE 71 ASIA PACIFIC: PET/CT SYSTEMS MARKET, BY TYPE, 2020–2028 (USD MILLION) 110
TABLE 72 ASIA PACIFIC: POSITRON EMISSION TOMOGRAPHY MARKET, BY APPLICATION, 2020–2028 (USD MILLION) 110
TABLE 73 ASIA PACIFIC: POSITRON EMISSION TOMOGRAPHY MARKET, BY END USER, 2020–2028 (USD MILLION) 111
9.4.1 CHINA 111
9.4.1.1 Healthcare reforms and investments to drive growth 111
TABLE 74 CHINA: POSITRON EMISSION TOMOGRAPHY MARKET, BY PRODUCT, 2020–2028 (USD MILLION) 112
TABLE 75 CHINA: PET/CT SYSTEMS MARKET, BY TYPE, 2020–2028 (USD MILLION) 112
9.4.2 JAPAN 112
9.4.2.1 Fast adoption of advanced technologies to propel growth 112
TABLE 76 JAPAN: POSITRON EMISSION TOMOGRAPHY MARKET, BY PRODUCT, 2020–2028 (USD MILLION) 113
TABLE 77 JAPAN: PET/CT SYSTEMS MARKET, BY TYPE, 2020–2028 (USD MILLION) 113
9.4.3 INDIA 113
9.4.3.1 Improving healthcare infrastructure to drive growth 113
TABLE 78 INDIA: POSITRON EMISSION TOMOGRAPHY MARKET, BY PRODUCT, 2020–2028 (USD MILLION) 114
TABLE 79 INDIA: PET/CT SYSTEMS MARKET, BY TYPE, 2020–2028 (USD MILLION) 114
9.4.4 AUSTRALIA 114
9.4.4.1 Increasing investments in research to provide opportunities for growth 114
TABLE 80 AUSTRALIA: POSITRON EMISSION TOMOGRAPHY MARKET, BY PRODUCT, 2020–2028 (USD MILLION) 115
TABLE 81 AUSTRALIA: PET/CT SYSTEMS MARKET, BY TYPE, 2020–2028 (USD MILLION) 115
9.4.5 SOUTH KOREA 115
9.4.5.1 Presence of advanced healthcare system to drive growth 115
TABLE 82 SOUTH KOREA: POSITRON EMISSION TOMOGRAPHY MARKET, BY PRODUCT, 2020–2028 (USD MILLION) 116
TABLE 83 SOUTH KOREA: PET/CT SYSTEMS MARKET, BY TYPE, 2020–2028 (USD MILLION) 116
9.4.6 REST OF ASIA PACIFIC 116
TABLE 84 REST OF ASIA PACIFIC: POSITRON EMISSION TOMOGRAPHY MARKET, BY PRODUCT, 2020–2028 (USD MILLION) 117
TABLE 85 REST OF ASIA PACIFIC: PET/CT SYSTEMS MARKET, BY TYPE, 2020–2028 (USD MILLION) 117
9.5 REST OF THE WORLD 117
TABLE 86 REST OF THE WORLD: POSITRON EMISSION TOMOGRAPHY MARKET, BY PRODUCT, 2020–2028 (USD MILLION) 118
TABLE 87 REST OF THE WORLD: PET/CT SYSTEMS MARKET, BY TYPE, 2020–2028 (USD MILLION) 118
TABLE 88 REST OF THE WORLD: POSITRON EMISSION TOMOGRAPHY MARKET, BY APPLICATION, 2020–2028 (USD MILLION) 118
TABLE 89 REST OF THE WORLD: POSITRON EMISSION TOMOGRAPHY MARKET, BY END USER, 2020–2028 (USD MILLION) 119
10 COMPETITIVE LANDSCAPE 120
10.1 OVERVIEW 120
10.2 STRATEGIES ADOPTED BY KEY PLAYERS 120
10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN POSITRON EMISSION TOMOGRAPHY MARKET 120
10.3 REVENUE SHARE ANALYSIS 121
FIGURE 28 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN POSITRON EMISSION TOMOGRAPHY MARKET, 2022 121
10.4 MARKET SHARE ANALYSIS 121
FIGURE 29 MARKET SHARE ANALYSIS OF TOP PLAYERS IN PET/CT MARKET, 2022 122
TABLE 90 POSITRON EMISSION TOMOGRAPHY MARKET: DEGREE OF COMPETITION 122
10.5 COMPETITIVE LEADERSHIP MAPPING FOR KEY PLAYERS (2022) 123
10.5.1 STARS 123
10.5.2 EMERGING LEADERS 124
10.5.3 PERVASIVE PLAYERS 124
10.5.4 PARTICIPANTS 124
FIGURE 30 POSITRON EMISSION TOMOGRAPHY MARKET: COMPETITIVE LEADERSHIP MAPPING FOR KEY PLAYERS, 2022 125
10.6 COMPETITIVE BENCHMARKING 126
TABLE 91 PRODUCT AND REGIONAL FOOTPRINT ANALYSIS OF TOP PLAYERS 126
TABLE 92 PRODUCT FOOTPRINT OF COMPANIES 126
TABLE 93 REGIONAL FOOTPRINT OF COMPANIES 127
10.7 COMPETITIVE SCENARIO AND TRENDS 128
TABLE 94 PRODUCT LAUNCHES 128
TABLE 95 DEALS 129
TABLE 96 OTHER DEVELOPMENTS 130
11 COMPANY PROFILES 131
11.1 KEY PLAYERS 131
(Business Overview, Products Offered, Recent Developments, and MnM View)*
11.1.1 GE HEALTHCARE 131
TABLE 97 GE HEALTHCARE: COMPANY OVERVIEW 131
FIGURE 31 GE HEALTHCARE: COMPANY SNAPSHOT (2022) 132
11.1.2 KONINKLIJKE PHILIPS N.V. 136
TABLE 98 KONINKLIJKE PHILIPS N.V.: COMPANY OVERVIEW 136
FIGURE 32 KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT (2022) 137
11.1.3 SIEMENS HEALTHINEERS 140
TABLE 99 SIEMENS HEALTHINEERS: COMPANY OVERVIEW 140
FIGURE 33 SIEMENS HEALTHINEERS: COMPANY SNAPSHOT (2022) 141
11.1.4 SHANGHAI UNITED IMAGING HEALTHCARE CO., LTD 143
TABLE 100 SHANGHAI UNITED IMAGING HEALTHCARE CO., LTD: COMPANY OVERVIEW 143
11.1.5 CANON INC. 146
TABLE 101 CANON INC.: COMPANY OVERVIEW 146
FIGURE 34 CANON INC.: COMPANY SNAPSHOT (2022) 147
11.1.6 SHIMADZU CORPORATION 149
TABLE 102 SHIMADZU CORPORATION: COMPANY OVERVIEW 149
FIGURE 35 SHIMADZU CORPORATION: COMPANY SNAPSHOT (2021) 150
11.1.7 MEDISO LTD. 152
TABLE 103 MEDISO LTD.: COMPANY OVERVIEW 152
11.1.8 MINFOUND MEDICAL SYSTEMS CO., LTD 154
TABLE 104 MINFOUND MEDICAL SYSTEMS CO., LTD: COMPANY OVERVIEW 154
11.1.9 NEUSOFT CORPORATION 156
TABLE 105 NEUSOFT CORPORATION: COMPANY OVERVIEW 156
FIGURE 36 NEUSOFT CORPORATION: COMPANY SNAPSHOT (2022) 157
11.1.10 ONCOVISION 158
TABLE 106 ONCOVISION: COMPANY OVERVIEW 158
11.1.11 POSITRON 159
TABLE 107 POSITRON: COMPANY OVERVIEW 159
11.1.12 MOLECUBES NV 160
TABLE 108 MOLECUBES NV: COMPANY OVERVIEW 160
11.1.13 CMR NAVISCAN 161
TABLE 109 CMR NAVISCAN: COMPANY OVERVIEW 161
11.1.14 KINDSWAY BIOTECH 162
TABLE 110 KINDSWAY BIOTECH: COMPANY OVERVIEW 162
11.1.15 BRAIN BIOSCIENCES, INC. 163
TABLE 111 BRAIN BIOSCIENCES, INC.: COMPANY OVERVIEW 163
* Business Overview, Products Offered, Recent Developments, and MnM View might not be captured in case of unlisted companies.
11.2 OTHER PLAYERS 164
11.2.1 SOFIE BIOSCIENCES 164
11.2.2 PRESCIENT MEDICAL IMAGING 164
11.2.3 REFLEXION 165
11.2.4 CUBRESA INC. 165
11.2.5 SYNCHROPET, INC. 166
12 APPENDIX 167
12.1 DISCUSSION GUIDE 167
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 170
12.3 CUSTOMIZATION OPTIONS 172
12.4 RELATED REPORTS 172
12.5 AUTHOR DETAILS 173
